Tata Elxsi and Bayer Launch Global Technology Centre for Radiology Medical Devices
Tata Elxsi has partnered with Bayer to establish a global technology center for medical devices in radiology at its Pune facility. The 'Bayer Development Centre in Radiology' will focus on co-developing advanced radiology devices, initially concentrating on Molecular Imaging. The center aims to accelerate time-to-market, enhance cost efficiency, and deliver innovative solutions meeting high regulatory standards. It leverages Tata Elxsi's healthcare engineering expertise and provides access to advanced laboratories, regulatory partnerships, and specialized talent. The collaboration is expected to strengthen Bayer's ability to deliver radiology solutions globally and advance innovation in diagnostic imaging.

*this image is generated using AI for illustrative purposes only.
Tata Elxsi , a global leader in design and technology services, has announced a significant partnership with Bayer, a prominent player in key areas of Radiology. The collaboration involves the establishment of a global technology center specializing in medical devices for radiology applications, marking a major step forward in medical technology innovation.
Global Technology Centre Launch
Tata Elxsi inaugurated the 'Bayer Development Centre in Radiology' at its Pune, India facility. This state-of-the-art center is designed to co-develop advanced radiology devices and technology with Bayer, focusing on enabling early and accurate diagnosis and treatment of critical illnesses.
Focus and Capabilities
The newly launched center will provide a wide range of engineering services for complex radiology devices, with an initial focus on Molecular Imaging. By combining design, development, and validation processes, the facility aims to:
- Accelerate time-to-market for new technologies
- Enhance cost efficiency in product development
- Deliver innovative solutions that meet the highest regulatory compliance standards
Leveraging Expertise and Ecosystems
This collaboration taps into Tata Elxsi's healthcare engineering expertise and the strengths of the Tata and India ecosystems. It provides access to:
- Advanced laboratories
- Regulatory partnerships
- Specialized technology talent
This strategic approach creates a scalable foundation for innovation and strengthens Bayer's ability to deliver radiology solutions across multiple geographies, including the US and EU.
Leadership Perspectives
Dr. Konstanze Diefenbach, Head of Research & Development, Radiology at Bayer, emphasized the company's commitment to innovation in diagnostic imaging, stating, "This new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer."
Sreevatsa Sahasranaman, Sr. Vice President & Head of Healthcare & Life Sciences at Tata Elxsi, highlighted the synergy between the two companies: "This centre is more than an engineering hub—it is where Bayer's radiology vision meets Tata Elxsi's design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability."
Impact on Healthcare Innovation
This partnership between Tata Elxsi and Bayer represents a significant step forward in the development of medical devices for radiology. By combining Bayer's expertise in radiology with Tata Elxsi's prowess in design and technology services, the collaboration aims to bring innovative, safe, and compliant solutions to patients and clinical staff worldwide.
The establishment of this global technology center is expected to play a crucial role in advancing the field of radiology, potentially leading to improved patient outcomes through more accurate and efficient diagnostic tools.
Historical Stock Returns for Tata Elxsi
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
-0.54% | +4.96% | +1.85% | +7.87% | -26.54% | +339.41% |